{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:23:16Z","timestamp":1715646196233},"reference-count":34,"publisher":"Japan Atherosclerosis Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2023,10,1]]},"DOI":"10.5551\/jat.63389","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T22:13:10Z","timestamp":1671747190000},"page":"1317-1326","source":"Crossref","is-referenced-by-count":2,"title":["Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics"],"prefix":"10.5551","volume":"30","author":[{"given":"Yung-An","family":"Chua","sequence":"first","affiliation":[{"name":"Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM) and Faculty of Medicine, Universiti Teknologi MARA (UiTM)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukma Azureen","family":"Nazli","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM) and Faculty of Medicine, Universiti Teknologi MARA (UiTM)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azhari","family":"Rosman","sequence":"additional","affiliation":[{"name":"National Heart Institute (IJN)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sazzli Shahlan","family":"Kasim","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM) and Faculty of Medicine, Universiti Teknologi MARA (UiTM)"},{"name":"Department of Cardiology, Faculty of Medicine, Universiti Teknologi MARA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khairul Shafiq","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Universiti Teknologi MARA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Bakhtiar","family":"Md Radzi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Universiti Teknologi MARA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor Alicezah","family":"Mohd Kasim","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM) and Faculty of Medicine, Universiti Teknologi MARA (UiTM)"},{"name":"Department of Pathology, Faculty of Medicine, Universiti Teknologi MARA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hapizah","family":"Nawawi","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM) and Faculty of Medicine, Universiti Teknologi MARA (UiTM)"},{"name":"Department of Pathology, Faculty of Medicine, Universiti Teknologi MARA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, and Wierzbicki AS: Familial hypercholesterolaemia. Nat Rev Dis Primers, 2017; 3: 17093","DOI":"10.1038\/nrdp.2017.93"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Vallejo-Vaz AJ, De Marco M, Stevens CaT, Akram A, Freiberger T, Hovingh GK, Kastelein JJP, Mata P, Raal FJ, Santos RD, Soran H, Watts GF, Abifadel M, Aguilar-Salinas CA, Al-Khnifsawi M, Alkindi FA, Alnouri F, Alonso R, Al-Rasadi K, Al-Sarraf A, Ashavaid TF, Binder CJ, Bogsrud MP, Bourbon M, Bruckert E, Chlebus K, Corral P, Descamps O, Durst R, Ezhov M, Fras Z, Genest J, Groselj U, Harada-Shiba M, Kayikcioglu M, Lalic K, Lam CSP, Latkovskis G, Laufs U, Liberopoulos E, Lin J, Maher V, Majano N, Marais AD, M\u00e4rz W, Mirrakhimov E, Miserez AR, Mitchenko O, Nawawi HM, Nordestgaard BG, Paragh G, Petrulioniene Z, Pojskic B, Postadzhiyan A, Reda A, Reiner \u017d, Sadoh WE, Sahebkar A, Shehab A, Shek AB, Stoll M, Su T-C, Subramaniam T, Susekov AV, Symeonides P, Tilney M, Tomlinson B, Truong T-H, Tselepis AD, Tybj\u00e6rg-Hansen A, V\u00e1zquez-C\u00e1rdenas A, Viigimaa M, Vohnout B, Wid\u00e9n E, Yamashita S, Banach M, Gaita D, Jiang L, Nilsson L, Santos LE, Schunkert H, Tokg\u00f6zo\u011flu L, Car J, Catapano AL, and Ray KK: Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018; 277: 234-255","DOI":"10.1016\/j.atherosclerosis.2018.08.051"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Chua Y-A, Razman AZ, Ramli AS, Kasim NaM, Nawawi HM, and Myhebat Fh Study Investigators: Familial hypercholesterolaemia in the Malaysian community: Prevalence, under-detection and under-treatment. J Atheroscler Thromb, 2021; 28: 1095-1107","DOI":"10.5551\/jat.57026"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, De Ferranti SD, and Ito MK: Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol, 2011; 5: 133-140","DOI":"10.1016\/j.jacl.2011.03.001"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Goldstein JL and Brown MS: A century of cholesterol and coronaries: from plaques to genes to statins. Cell, 2015; 161: 161-172","DOI":"10.1016\/j.cell.2015.01.036"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, De Ferranti S, Faiella-Tommasino J, and Forman DE: 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2019; 73: e285-e350","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Couture P and Lamarche B: Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond. Curr Opin Lipidol, 2013; 24: 227-232","DOI":"10.1097\/MOL.0b013e3283613a55"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Besseling J, Hovingh GK, Huijgen R, Kastelein JJ, and Hutten BA: Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. J Am Coll Cardiol, 2016; 68: 252-260","DOI":"10.1016\/j.jacc.2016.04.054"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Vuorio A, Docherty KF, Humphries SE, Kuoppala J, and Kovanen PT: Statin treatment of children with familial hypercholesterolemia\u2013trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis, 2013; 226: 315-320","DOI":"10.1016\/j.atherosclerosis.2012.10.032"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, and Kastelein JJ: Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ, 2008; 337: a2423","DOI":"10.1136\/bmj.a2423"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Pandor A, Ara R, Tumur I, Wilkinson A, Paisley S, Duenas A, Durrington P, and Chilcott J: Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta\u2010analysis of randomized controlled trials. J Intern Med, 2009; 265: 568-580","DOI":"10.1111\/j.1365-2796.2008.02062.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, and Defesche JC: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J, 2013; 34: 3478-3490","DOI":"10.1093\/eurheartj\/eht273"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Abdul-Razak S, Rahmat R, Kasim AM, Rahman TA, Muid S, Nasir NM, Ibrahim Z, Kasim S, Ismail Z, Ghani RA, Sanusi AR, Rosman A, and Nawawi H: Diagnostic performance of various familial hypercholesterolaemia diagnostic criteria compared to Dutch Lipid Clinic Criteria in an Asian population. BMC Cardiovasc Disord, 2017; 17: 264","DOI":"10.1186\/s12872-017-0694-z"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Azraii AB, Ramli AS, Ismail Z, Abdul-Razak S, Mohd-Kasim NA, Ali N, Watts GF, and Nawawi H: Knowledge, awareness and practice regarding familial hypercholesterolaemia among primary care physicians in Malaysia: The importance of professional training. Atherosclerosis, 2018; 277: 508-516","DOI":"10.1016\/j.atherosclerosis.2018.08.018"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Pang J, Chan DC, Hu M, Muir LA, Charng M-J, Florkowski CM, George PM, Lin J, Marais AD, and Nawawi HM: Comparative aspects of the care of familial hypercholesterolemia in the \u201cTen Countries Study\u201d. J Clin Lipidol, 2019; 13: 287-300","DOI":"10.1016\/j.jacl.2019.01.009"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Park JE, Chiang C-E, Munawar M, Pham GK, Sukonthasarn A, Aquino AR, Khoo KL, and Chan HWR: Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol, 2012; 19: 781-794","DOI":"10.1177\/1741826710397100"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M-R, Tokgozoglu L, Wiklund O, and Group ESD: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J, 2019; 41: 111-188","DOI":"10.15829\/1560-4071-2020-3826"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Silva PR, Jannes CE, Oliveira TG, Miname MH, Rocha VZ, Chacra AP, Gurgel MHC, Montenegro RM, Sobrinho CRMR, and Moreira ASB: Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil. Atherosclerosis, 2017; 263: 257-262","DOI":"10.1016\/j.atherosclerosis.2017.06.917"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Ellis KL, Pang J, Chan DC, Hooper AJ, Bell DA, Burnett JR, and Watts GF: Familial combined hyperlipidemia and hyperlipoprotein (a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions. J Clin Lipidol, 2016; 10: 1329-1337","DOI":"10.1016\/j.jacl.2016.08.011"},{"key":"20","unstructured":"20) Ministry of Health Malaysia, Management of Dyslipidaemia 2017, M.o.H. Malaysia, Editor. 2017, Ministry of Health: Malaysia"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) D\u2019agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, and Kannel WB: General cardiovascular risk profile for use in primary care. Circulation, 2008; 117: 743-753","DOI":"10.1161\/CIRCULATIONAHA.107.699579"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Khera AV, Won H-H, Peloso GM, Lawson KS, Bartz TM, Deng X, Van Leeuwen EM, Natarajan P, Emdin CA, and Bick AG: Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol, 2016; 67: 2578-2589","DOI":"10.1016\/j.jacc.2016.03.520"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, and Pedersen TR: 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis, 2016; 253: 281-344","DOI":"10.1016\/j.atherosclerosis.2016.08.018"},{"key":"24","unstructured":"24) De Isla LP, Alonso R, Watts GF, Mata N, Cerezo AS, Mu\u00f1iz O, Fuentes F, Diaz-Diaz JL, De Andr\u00e9s R, and Zamb\u00f3n D: Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up. J Am Coll Cardiol, 2016; 67: 1278-1285"},{"key":"25","unstructured":"25) Chan R, Chan P, Chan K, Lam SC, Hai JJ, Wong MK, Tam F, Lam L, Chan C, and Lam Y: The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre. Hong Kong Med J, 2012; 18: 395-406"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Teramoto T, Uno K, Miyoshi I, Khan I, Gorcyca K, Sanchez RJ, Yoshida S, Mawatari K, Masaki T, and Arai H: Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan. Atherosclerosis, 2016; 251: 248-254","DOI":"10.1016\/j.atherosclerosis.2016.07.001"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Teramoto T, Kai T, Ozaki A, Crawford B, Arai H, and Yamashita S: Treatment patterns and lipid profile in patients with familial hypercholesterolemia in Japan. J Atheroscler Thromb, 2018; 25: 580-592","DOI":"10.5551\/jat.41483"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Murakami Y, Okamura T, Nakamura K, Miura K, and Ueshima H: The clustering of cardiovascular disease risk factors and their impacts on annual medical expenditure in Japan: community-based cost analysis using Gamma regression models. BMJ Open, 2013; 3: e002234","DOI":"10.1136\/bmjopen-2012-002234"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Tan CS, Kaur HJ, Seng LK, Manan MM, Faizal SM, Menon S, and Cha XX: Utilization Pattern of Lipid Modifying Agents in An Outpatient Pharmacy Department of a Private Hospital in Malaysia. Malaysian Journal of Pharmacy (MJP), 2020; 6: 22-24","DOI":"10.52494\/LMJS6138"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Pang J, Hu M, Lin J, Miida T, Nawawi HM, Park JE, Wu X, Ramli AS, Kim NT, and Gonzalez-Santos LE: An enquiry-based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: The \u201cTen Countries Study\u201d. BMJ Open, 2017; 7: e017817","DOI":"10.1136\/bmjopen-2017-017817"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, and Sullivan D: PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet, 2015; 385: 331-340","DOI":"10.1016\/S0140-6736(14)61399-4"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, and Lorenzato C: ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J, 2015; 36: 2996-3003","DOI":"10.1093\/eurheartj\/ehv370"},{"key":"33","unstructured":"33) Ministry of Health Malaysia, National Health and Morbidity Survey 2019 - Non-communicable Disease: Risk Factors and other Health Problems. 2020"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Wu L and Parhofer KG: Diabetic dyslipidemia. Metabolism, 2014; 63: 1469-1479","DOI":"10.1016\/j.metabol.2014.08.010"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/10\/30_63389\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:54:19Z","timestamp":1715576059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/10\/30_63389\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.63389","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,1]]},"article-number":"63389"}}